Literature DB >> 2355895

Prevalence of naevocytic naevi after chemotherapy for childhood cancer.

P E de Wit1, G A de Vaan, T M de Boo, W A Lemmens, F H Rampen.   

Abstract

The frequency of naevocytic naevi (moles) in patients with childhood haematologic malignancies was studied. All patients had received multiple chemotherapy. The majority had also received cranial irradiation as part of their central nervous system leukaemia/lymphoma prophylaxis. Total body mole counts of the patients were compared with those of their healthy brothers and sisters. The median number of moles in the patient group was 20.0 (n = 79), in the healthy sibs 11.0 (n = 88). In two subgroups mole counts of male and female patients were compared with those of their closet brother or sister. There were 19 male and 19 female pairs for comparison. Median numbers of moles were significantly higher in both patient groups than in the controls (P less than 0.05). It is suggested that multiple chemotherapy (and/or cranial irradiation) may induce or activate naevocytic naevi. These findings may have important implications with regard to the aetiology of melanoma.

Entities:  

Mesh:

Year:  1990        PMID: 2355895     DOI: 10.1002/mpo.2950180417

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

Review 1.  Melanoma risk factors and atypical moles.

Authors:  M L Williams; R W Sagebiel
Journal:  West J Med       Date:  1994-04

2.  Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi.

Authors:  E A Baird; P M McHenry; R M MacKie
Journal:  BMJ       Date:  1992-10-03

3.  Melanocytic naevi and melanoma in survivors of childhood cancer.

Authors:  A Green; P Smith; W McWhirter; P O'Regan; D Battistutta; M E Yarker; K Lape
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

Review 4.  Congenital Glioblastoma multiforme and eruptive disseminated Spitz nevi.

Authors:  Victor Desmond Mandel; Flavia Persechino; Alberto Berardi; Giovanni Ponti; Silvana Ciardo; Cecilia Rossi; Giovanni Pellacani; Francesca Farnetani
Journal:  Ital J Pediatr       Date:  2016-05-14       Impact factor: 2.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.